NICE Recommends Mobocertinib for Advanced EGFR+ NSCLC with Exon 20 Insertion
The United Kingdom’s National Institutes for Health Care Excellence (NICE) recently recommended the use of mobocertinib to treat advanced EGFR exon 20 insertion gene mutation-positive non-small-cell lung cancer (NSCLC) in patients who have already received platinum-based chemotherapy.
Given there is currently no standard treatment for exon 20 insertion mutation-positive NSCLC in the UK, this recommendation addresses an unmet clinical need for patients with this rare form of non-small cell lung cancer.
The treatment was licensed through Project Orbis, an international program to review and approve promising cancer drugs helping patients access treatments faster.
According to NICE, this is the 19th lung cancer drug recommended by the organization in the past three years, with a total of about 18,000 people now eligible to receive these treatments.
“I’m delighted that we have been able to recommend this innovative treatment for patients in England with this rare and aggressive form of lung cancer,” said Helen Knight, interim director of medicines evaluation at NICE. “This is the first treatment approved by NICE that targets this specific gene mutation in people with advanced non-small-cell lung cancer. The evidence shows it not only extends people’s lives but also extends how long people have before their cancer gets worse.”
Early Registration Savings for LALCA 2023 End Soon
Register for the 2023 Latin America Conference on Lung Cancer (LALCA) by Friday, December 16, to receive early registration savings. The conference will take place January 25 to 27, 2023, at the Radisson Hotel Montevideo Victoria Plaza in Montevideo, Uruguay.
LALCA 2023 provides a unique opportunity for participants to attend lectures by international, regional, and local experts on key advances in the science of treating, detecting, and preventing lung cancer and other thoracic malignancies. This is a multidisciplinary program designed for all healthcare professionals involved in the management and treatment of patients with thoracic malignancies. This conference provides an excellent opportunity to collaborate with thoracic oncology specialists based in Latin America.
Registration Opens for TTLC 2023
For the first time since 2020, the Targeted Therapies of Lung Cancer Meeting (TTLC) will offer face-to-face education, collaboration, and networking in 2023. TTLC 2023 will take place from February 22 to 25 at the Fairmont Miramar in Santa Monica, California. Live-stream and on-demand programming will be available for virtual attendees. Meeting and accommodation registration is now open.
In keeping with its long tradition, TTLC presentations will summarize the data on relevant targets for new therapies and share data on preclinical and early clinical data for each of the drugs directed at these targets. Find more information, including the preliminary program, at ttlc2023.iaslc.org.